PRT12396 (mutant-selective JAK2V617F inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- February 3 — Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396: FDA cleared the IND application for PRT12396, a mutant-selective allosteric JAK2V617F inhibitor targeting the JH2 deep pocket, enabling initiation of first-in-human clinical trials in MPNs (regulatory milestone; no clinical efficacy or safety data yet). (novelty: 3)
Open questions
Related
Contributing findings
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396
February 3, 2026
novelty 3
per-area 4
introduces